Medicine pack check sheet

Source-linked reading points

• 100 mg/4 mL and 25 mg/mL are total-content and concentration clues for this exact single-dose vial, not answers to “how much to infuse,” “can it be shared,” or “can it be handled at home.” Preparation, dilution, infusion, remaining-product handling and each visit plan for an intravenous product belong to the treating facility under the current label and prescription.
• Being called immunotherapy, a PD-1/PD-L1 antibody or an intravenous medicine does not make KEYTRUDA self-combinable, alternatable, catch-up replaceable or substitutable with OPDIVO, chemotherapy, targeted therapy, steroids or another biologic. Tumour type, pathology/molecular testing, prior regimen, organ function and the full medicine list require integrated oncology-team review.
• The label notes immune-mediated reactions that may involve lungs, bowel, liver, endocrine organs, kidneys and skin, as well as infusion-related reactions. New or worsening breathing difficulty, persistent diarrhoea, jaundice-like changes, unusual fatigue/mental-status change, changed urine output, severe rash, fever/chills or another acute concern needs prompt contact with the treatment team or local urgent medical support rather than waiting to self-assess at the next infusion.
• Test names such as PD-L1, MSI-H, dMMR and TMB-H appear in label conditions for some indications, but seeing a test name, value or online interpretation cannot confirm that an individual fits KEYTRUDA. Specimen, method, disease setting, combination plan and the current target-market label require oncology-team interpretation.